Nesolicaftor - Kineta
Alternative Names: PTI-428Latest Information Update: 28 Feb 2024
At a glance
- Originator Proteostasis Therapeutics
- Developer Kineta
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cystic fibrosis
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 31 Dec 2023 Nesolicaftor licensed to Fair Therapeutics
- 19 Dec 2022 Yumanity Therapeutics has merged with Kineta to form Kineta
- 28 Sep 2022 No development reported - Phase-II for Cystic fibrosis (Combination therapy) in Canada, Western Europe, New Zealand, USA (PO) (Yumanity Therapeutics website, September 2022)